纳米药物设计与负责任创新:建构论视角的解释  

The Design of Nano-drug and Responsible Innovation: The Interpretation from Constructivism Perspective

作　　者：赵迎欢[1] Brbel Dorbeck-Jung 

机构地区：[1]中国沈阳药科大学社会科学部,辽宁沈阳110016 [2]Faculty of Management and Governance,University of Twente

出　　处：《科技管理研究》2016年第1期257-261,共5页Science and Technology Management Research

基　　金：国家社会科学基金项目"设计伦理视角下纳米制药技术风险及责任控制问题研究"(12BZX030)

摘　　要：药物设计是药品生命周期的起始阶段,也是控制药品风险的关键环节。纳米药物设计是实现风险控制的"源头"治理,设计过程采用的价值敏感设计(价值嵌入)方法是设计者负责任创新意识的展现。由纳米制剂的结构效应和尺寸效应客观决定的纳米药物设计者责任,不仅表现为对纳米药物风险的技术评估(TA)的责任,而且需要从建构论视角探索纳米药物风险的建构性技术评估(CTA)体系。建构性纳米药物风险评估的理论基础是马克思主义的"人本"理论和利益相关者理论。纳米药物设计者实施负责任创新的路径应关注知识提升、道德规范、法律制约及政策导向4个维度。The design of drug is the initial stage of life cycle of a drug, and it is also a key link to control the risk of drug. The design of Nano - drug will be to realize the risk control of the ＂origin＂ governance. The method of value sensitive design （value embedded） used to design process showed the consciousness of responsible innovation of designers. The responsibility of designers objectively caused by the structure effect and size effect of nano - preparation not only includes the responsibility of the technical assessment （TA） related to risk of nano - drug, and but also needs to study a system of con- struetive technology assessment （CTA） linking with risk from the constructivism perspective. The theory basis for construc- ting risk assessment of Nano - drug is the humanism theory of Marxism and stakeholder theory. The designers of Nano - drug implement the path of responsible innovation which should pay attention to the four dimensions of promotion of knowl- edge, codes of ethics, legal constraints and policy orientation.

关 键 词：建构性技术评估 设计者责任 负责任创新 人本理论 利益相关者理论 

分 类 号：R943[医药卫生—药剂学] TB383.1[医药卫生—药学]